- Home
- SNDX vs LILAK Comparison
SNDX vs LILAK Comparison
Compare SNDX & LILAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNDX
- LILAK
- Stock Information
- Founded
- SNDX 2005
- LILAK 2017
- Country
- SNDX United States
- LILAK Bermuda
- Employees
- SNDX N/A
- LILAK N/A
- Industry
- SNDX Biotechnology: Pharmaceutical Preparations
- LILAK Cable & Other Pay Television Services
- Sector
- SNDX Health Care
- LILAK Telecommunications
- Exchange
- SNDX Nasdaq
- LILAK Nasdaq
- Market Cap
- SNDX 1.1B
- LILAK 1.1B
- IPO Year
- SNDX 2016
- LILAK N/A
- Fundamental
- Price
- SNDX $9.92
- LILAK $7.14
- Analyst Decision
- SNDX Strong Buy
- LILAK Buy
- Analyst Count
- SNDX 11
- LILAK 3
- Target Price
- SNDX $34.00
- LILAK $10.27
- AVG Volume (30 Days)
- SNDX 1.7M
- LILAK 1.5M
- Earning Date
- SNDX 08-04-2025
- LILAK 08-05-2025
- Dividend Yield
- SNDX N/A
- LILAK N/A
- EPS Growth
- SNDX N/A
- LILAK N/A
- EPS
- SNDX N/A
- LILAK N/A
- Revenue
- SNDX $43,722,000.00
- LILAK $4,441,000,000.00
- Revenue This Year
- SNDX $431.08
- LILAK $2.45
- Revenue Next Year
- SNDX $105.38
- LILAK $3.11
- P/E Ratio
- SNDX N/A
- LILAK N/A
- Revenue Growth
- SNDX N/A
- LILAK N/A
- 52 Week Low
- SNDX $8.58
- LILAK $4.23
- 52 Week High
- SNDX $23.37
- LILAK $10.93
- Technical
- Relative Strength Index (RSI)
- SNDX 51.66
- LILAK 70.80
- Support Level
- SNDX $9.42
- LILAK $6.65
- Resistance Level
- SNDX $10.75
- LILAK $7.10
- Average True Range (ATR)
- SNDX 0.58
- LILAK 0.31
- MACD
- SNDX 0.08
- LILAK 0.01
- Stochastic Oscillator
- SNDX 51.74
- LILAK 93.33
About SNDX Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
About LILAK Liberty Latin America Ltd. Class C
Liberty Latin America Ltd is a telecommunications company. It is a provider of video, broadband internet, fixed-line telephony, and mobile services to residential and business customers. The company's reportable segments include C&W Caribbean, Liberty Networks, C&W Panama, VTR, Liberty Puerto Rico and Liberty Costa Rica. The company generates the majority of its revenue from C&W Caribbean, and Liberty Puerto Rico segments.